Clinicopathological Characteristics of Metastatic Colorectal Cancer Patients with Prolonged Survival

Le résumé fourni par la source

Objective: The median overall survival (OS) of metastatic colorectal cancer (mCRC) has reached 30 months in recent trials; however, data on the the clinicopathological features of long-term survivors remain limited. Material and Methods:This is a single-center retrospective analysis of the clinical, pathological, and genetic characteristics of patients who survived more than 30 months after diagnosis of mCRC.Results: Fifty-eight patients were included; mean age was 59.7±10.0years.At diagnosis, 63.8% of patients had stage 4 disease and 84.5% had leftsided tumors.All underwent primary tumor surgery; a KRAS mutation was present in 48.3% of patients.Of the patients, 84.5% received local treatment, with metastasectomy being the most common (70.7%).The identified mutations were PIK3A (3 patients), SMAD4 (2), ERBB3 (1), MAP2K and FGFR (1), and germline POL (1) mutations.The most common metastatic sites were the liver (65.5%), the lungs (56.9%), and the peritoneum (15.5%).The Fluoropyrimidine-oxaliplatin combination was the most commonly used first-line treatment (59.6%).The median OS was not reached (range: 31.5-217.03months).Univariate analysis identified female gender (p=0.019),KRAS mutation (p=0.033),higher number of metastatic lesions (p=0.016),increased number of treatment lines (p=0.001), and liver metastases in segments 6 (p<0.001) and 8 (p=0.007) as poor prognostic factors.Multivariate analysis confirmed that female sex (p=0.036),KRAS mutation (p=0.02),liver metastasis in segment 6 (p=0.018), and an increased number of treatment lines (p=0.007) were associated with poorer survival. Conclusion:Patients with mCRC and above-average survival constituted a heterogeneous group.However, female sex, KRAS mutation, and segment 6 liver metastasis were associated with poor prognosis.Primary tumor surgery may have contributed to prolonged survival, warranting further comparative studies to guide clinical decisions.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.